Background Hematopoietic stem cells have the capacity to self-renew as well as to differentiate and thus ensure blood production throughout life. The balance between self-renewal and differentiation is well controlled to avoid hyper-proliferative conditions like leukemia. Chromobox 7 (CBX7) plays an important role in regulating this balance. CBX7 can recognize H3K27me3 which will induce Polycomb Repressive Complex 1 (PRC1)-dependent gene repression, including genes required for differentiation and cell cycle arrest. In this study, we tested existing and newly synthesized CBX7 inhibitors to investigate whether they block proliferation and induce differentiation of human myeloid and lymphoid leukemic cell lines and primary cells. Results Pharmacological inhibition of CBX7 led to reduction of H2Aub levels, loss of CBX7 binding to differentiation and cell cycle arrest target genes, reduced viability and proliferation, and terminal differentiation of leukemic cells. Beyond canonical binding to H3K27me3, we recently showed that CBX7 can recognize the histone H3K9 methyltransferases SETDB1 and EHMT, suggesting that CBX7 regulates the balance between proliferation and differentiation by canonical and non-canonical interactions. Indeed, CBX7 inhibitors reduced H3K9me2/3 levels in leukemic cells and prevented the binding of CBX7 to SETDB1 and EHMT. SETDB1 or EHMT inhibitors alone phenocopied the effect of the CBX7 inhibitors, as they reduced viability and induced differentiation. Interestingly, SETDB1 or EHMT inhibitors synergized with CBX7 inhibitors in leukemic cells. Conclusion This study demonstrates that inhibition of CBX7 alone, or in combination with inhibiting SETDB1 or EHMT, blocks proliferation and induces differentiation of leukemic cells. Therefore, pharmacological targeting of CBX7 may constitute a novel therapeutic approach in leukemia. Hematopoietic stem cells have the capacity to self-renew as well as to differentiate and thus ensure blood production throughout life. The balance between self-renewal and differentiation is well controlled to avoid hyper-proliferative conditions like leukemia. Chromobox 7 (CBX7) plays an important role in regulating this balance. CBX7 can recognize H3K27me3 which will induce Polycomb Repressive Complex 1 (PRC1)-dependent gene repression, including genes required for differentiation and cell cycle arrest. In this study, we tested existing and newly synthesized CBX7 inhibitors to investigate whether they block proliferation and induce differentiation of human myeloid and lymphoid leukemic cell lines and primary cells. Pharmacological inhibition of CBX7 led to reduction of H2Aub levels, loss of CBX7 binding to differentiation and cell cycle arrest target genes, reduced viability and proliferation, and terminal differentiation of leukemic cells. Beyond canonical binding to H3K27me3, we recently showed that CBX7 can recognize the histone H3K9 methyltransferases SETDB1 and EHMT, suggesting that CBX7 regulates the balance between proliferation and differentiation by canonical and non-canonical interactions. Indeed, CBX7 inhibitors reduced H3K9me2/3 levels in leukemic cells and prevented the binding of CBX7 to SETDB1 and EHMT. SETDB1 or EHMT inhibitors alone phenocopied the effect of the CBX7 inhibitors, as they reduced viability and induced differentiation. Interestingly, SETDB1 or EHMT inhibitors synergized with CBX7 inhibitors in leukemic cells. This study demonstrates that inhibition of CBX7 alone, or in combination with inhibiting SETDB1 or EHMT, blocks proliferation and induces differentiation of leukemic cells. Therefore, pharmacological targeting of CBX7 may constitute a novel therapeutic approach in leukemia.